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Abstract
Background: Pediatric-based or -inspired trials have improved the prognosis of ado-
lescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) 
acute lymphoblastic leukemia (ALL).
Methods: This study reports the results of treatment of the ALLRE08 trial, a full 
pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL.
Results: From 2008 to 2018, 89 patients (38 adolescents [15-18  years] and 51 
young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the 
ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were 
transferred to a high-risk (HR) protocol because of poor marrow response on day 14 
(n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, 
n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-
47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 
52% (34%-67%), P =  .012. No treatment-related mortality was observed in 66/66 
patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The esti-
mated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly 
higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), 
P = .021. Although CIR or OS were lower in patients who were transferred to a HR 
trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% 
[14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]).
Conclusion: A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-
ALL, with better results for adolescents than for YA. Outcome of patients with poor 
early response rescued with a HR trial was not significantly inferior.
K E Y W O R D S
acute lymphoblastic leukemia, adolescents and young adults, pediatric treatment
1 |  INTRODUCTION
In recent years, the results of treatment of adolescents and 
young adults (AYA) diagnosed with ALL have significantly 
improved with the use of pediatric-based or -inspired pro-
tocols.1-3 This was first observed when retrospective stud-
ies demonstrated clear differences in outcomes for AYA 
depending on enrollment in pediatric vs adult cooperative 
group studies, despite most adult treatment regimens evolv-
ing from a pediatric background. These improvements 
have also been confirmed in population-based studies.4 
However, the design of pediatric trials significantly differs 
from that of adult trials.5 Pediatric trials involve more in-
tensive dosing of key therapeutic agents in ALL, including 
vincristine, steroids, and asparaginase, while fewer mye-
losuppressive drugs such as anthracyclines and cytarabine 
are used in these trials. In addition, hematopoietic stem cell 
transplantation (HSCT) is less used in pediatric trials.6,7 
Other factors contributing to the differences between the 
two types of trials relate to the greater experience observed 
in pediatric centers and higher adherence of AYA treated 
in pediatric vs adult cancer centers in some countries.7-10 
However, a recently published study by three adult US co-
operative groups (CALGB, ECOG, and SWOG) demon-
strated that the use of a full pediatric regimen for young 
adults (YA) with ALL up to the age of 40 years was feasi-
ble and effective, resulting in improved survival rates com-
pared to historical controls.11
In 1996 the Spanish PETHEMA (Programa Español 
de Tratamientos en Hematología) Group conducted a 
full pediatric trial (ALL96) to treat Philadelphia chromo-
some-negative (Ph-neg) AYA up to the age of 30  years, 
showing no significant differences in outcome between 
adolescents (15-18 years) and YA (19-30 years).12 At the 
time of the design of the trial the assessment of minimal 
residual disease (MRD) for tailored treatment was not ex-
tensively employed. In 2007, the PETHEMA Group devel-
oped another trial (ALLRE08) incorporating MRD to the 
decision-making process without changing the inclusion 
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criteria and the chemotherapy schedule. This study reports 
the outcomes of the Ph-neg AYA ALL patients included in 
this latter trial.
2 |  PATIENTS AND METHODS
2.1 | Eligibility
From August 2008 to April 2018, adolescents (age range: 
15 to 18  years) and YA age range: 19 to 30  years) with 
standard-risk (SR) Ph-neg ALL were enrolled in the 
ALLRE08 PETHEMA trial (clinicaltrials.gov identifier: 
NCT02036489). SR-ALL was defined for both B-cell pre-
cursor ALL or T-ALL patients who fulfilled all the follow-
ing criteria: a white blood cell count ≤ 30×109/L, absence 
of t(9;22)/BCR-ABL rearrangements or t(4;11), or any 
other 11q23/KMT2A gene rearrangement. This definition 
base on a minimal set of criteria was identical to that of 
the ALL-96 trial and allowed a homogeneous recruitment 
of patients by the participating centers. Patients were not 
eligible if they had previously received antileukemic treat-
ment, or had uncontrolled or severe cardiovascular (history 
of congestive heart failure [New York Heart Association 
class III or IV] or left ventricular ejection  <  40%), he-
patic (total serum bilirubin > 1.5 × the upper normal limit 
[ULN], not attributable to ALL) or renal disease (serum 
creatinine  >  1.5  ×  ULN and estimated creatinine clear-
ance  <  40  mL/minute [Cockcroft-Gault formula] not at-
tributable to ALL) or had a severe psychiatric condition 
(mental illness that does not allow to follow the protocol 
according to the physicians criteria). Patients with mature 
B ALL, Ph-positive ALL, T or B-cell lymphoblastic lym-
phoma or those with mixed phenotype acute leukemia were 
not included in the trial. Patients were centrally registered 
after informed consent was obtained from adult patients or 
from parents or guardians for patients under 18 years. The 
study was approved by the Institutional Review Boards of 
all the participating centers.
2.2 | Diagnostic procedure
ALL was defined based on bone marrow (BM) infil-
tration of  >  20% of blasts with lymphoid morphology. 
Immunophenotyping was performed by flow cytometry with 
monoclonal antibodies against with B-cell, T-cell, myeloid, 
and precursor cell-associated antigens, and B or T lineage 
commitment was defined based on the WHO 2008 crite-
ria. Chromosomal analyses (using direct methods and un-
stimulated short-term cultures with G-banding) of BM or 
peripheral blood (PB) samples performed at diagnosis were 
centrally reviewed. A minimum of 20 metaphase cells were 
required to define a normal karyotype. Fluorescence in situ 
hybridization (FISH) studies for BCR-ABL1, KMT2A, MYC, 
and TCF3-PBX1 were performed in cases without a valid cy-
togenetic study.
2.3 | Minimal residual disease assessment
Bone marrow MRD levels were assessed at each participat-
ing center in CR patients at: i) end of induction (weeks 5-6) 
in CR patients, ii) end of consolidation/reinduction (weeks 
19-20), iii) end of the fourth reinduction cycle (weeks 25-26), 
and iv) end of maintenance (week 106-108) using a 4-color 
multiparameter flow cytometry (FCM) approach with a limit 
of detection of 10-4.
2.4 | Treatment and response criteria
Treatment (Table 1) consisted of a prephase with pred-
nisone (maximum of 1  week) and one dose of triple in-
trathecal therapy (TIT) with methotrexate, cytarabine, and 
hydrocortisone given while ALL was being fully character-
ized. Subsequently, the patients received induction therapy. 
Patients with morphologic CR and lower MRD levels (de-
fined as < 0.25% in this trial) received consolidation therapy 
followed by reinduction. Maintenance therapy with monthly 
reinforcement cycles (M-1) was administered up to 1 year 
after ALL diagnosis. Then a second phase of maintenance 
therapy without reinforcement (M-2) with mercaptopurine 
plus methotrexate was administered up to 2 years to patients 
in continuous CR. CNS prophylaxis included the admin-
istration of 14 courses of TIT over the 2 years of therapy. 
Cumulative doses of the main cytotoxic drugs were as fol-
lows: 24 mg vincristine, 5,150 mg/m2 prednisone, 175 mg/
m2 dexamethasone, 320,000  IU/m2 native E coli asparagi-
nase (pegylated formulation of asparaginase was not licensed 
in Spain at the time of this protocol), 240 mg/m2 daunoru-
bicin, 2,200  mg/m2 cyclophosphamide, and 9,000  mg/m2, 
24-h continuous IV infusion methotrexate plus 1,560  mg/
m2 IM methotrexate during maintenance. Hospitalization, 
prophylaxis and management of infections, transfusion, and 
other supportive care therapies were carried out according 
to institutional protocols. Therapeutic dose monitoring of 
asparaginase was not performed.
Patients with poor early cytological response (defined as 
BM blast cells  ≥  10% on day 14 of induction), or MRD 
level  ≥  0.05% at the end of reinduction or after the 4th 
monthly reinforcement cycle were considered as high-risk 
(HR) patients and entered in the ALL-HR PETHEMA trial 
active at that time (ALLHR0313 [NCT 00853008] until 
2010 and ALLHR1114 [NCT01540812] from 2011 to 2019) 
(Table S1).
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2.5 | Outcome assessment
The primary endpoints of this study were: i) CR rate, ii) cu-
mulative incidence of relapse (CIR), and iii) overall survival 
(OS). Secondary objectives included assessment of toxicity 
and comparison with ALL96 trial outcomes (updated for this 
study). Planned enrollment was of 90 patients to allow com-
parison with the ALL96 trial.
T A B L E  1  PETHEMA ALLRE08 protocol. Chemotherapy schedule
Phase Drugs Week Route Dose Days
Prephasea 
Prednisone 1 IV 60 mg/m2 1-7
Triple IT therapy 1 IT 1
MTX 1 IT 15mg 1
ARA-C 1 IT 30 mg 1
Hydrocortisone 1 IT 20 mg 1
Remission induction
Vincristine 1-4 IV 2 mg (absolute) 1, 8, 15, 22
Prednisone 1-5 IV/PO 60 mg/m2 1-27
IV/PO 30 mg/m2 28-35
Asparaginase (E coli, native) 2-4 IV 10,000 IU/m2 1-12, 17-19, 24-26
5 IV 1,000 mg/m2 35
Cyclophosphamide 1, 5 IT 1, 29
Triple IT Therapy
Consolidation
Mercaptopurine 1 PO 50 mg/m2 1-7
Methotrexate 1, 4, 8 IV (24h) 3 g/m2 b 1, 28, 56
Teniposide 150 mg/m2/12h 14, 42
ARA-C 2,6 IV 14, 42
Triple IT therapy 2,6
1, 4, 8
IV
IT
500 mg/m2/12h 1, 28, 56
Reinduction
Dexamethasone 1, 2 IV/PO 10 mg/m2 1-14
Vincristine 1-3 IV/PO
IV
5 mg/m2
2 mg (absolute)
15-21
1, 8, 15
Daunorubicin 1, 2 IV 30 mg/m2 1-2, 8-9
Asparaginase (E coli, native) 1, 3 IM/IV 10,000 IU/m2 1-3, 15-17
Triple IT Therapy 1, 3 IT 1, 15
Maintenance with reinforcement
Maintenance IM 20 mg/m2/week Until week 52
Methotrexate PO Until week 52
Mercaptopurine 50 mg/m2/d
Reinductions 1 IV 1, until week 52
Vincristine 1 IV/PO 2 mg (absolute) 1-7, until week 52
Prednisone 1 IV 60 mg/m2 1, until week 52
Asparaginase (E coli, native) 20,000 IU/m2
Maintenance without reinforcement
Methotrexate IM 20 mg/m2/week Until week 105
Mercaptopurine PO 50 mg/m2/d Until week 105
Abbreviations: ARA-C, cytarabine; IM, intramuscular; IT, intrathecal; IV, intravenous; MTX, methotrexate; PO, oral.
aDuration of less than 1 week if ALL has been well characterized. 
bWith folinic acid rescue. 
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CR was defined as the absence of clinical manifes-
tations of ALL, neutrophil count  >  1.5×109/L, plate-
let count  >  150×109/L, and hemoglobin level  >  100  g/L, 
with < 5% of blast cells in BM. Patients with ≥ 5% BM blast 
cells at the end of the induction phase were considered as 
induction failures. Two patterns of early response were con-
sidered in BM aspirate performed on day 14 of treatment: 1) 
slow, defined as the presence of ≥ 10% of blast cells, and 2) 
standard, defined as < 10% BM blast cells or hypoplastic BM. 
Overall survival was defined as the time from study entry to 
death or last follow-up. Event-free survival was defined as the 
time from diagnosis to failure, relapse or death by any cause or 
last follow-up. The Common Terminology Criteria for Adverse 
Events (CTCAE v 3.0) was used for analysis of toxicity.
2.6 | Statistical analysis
Patients’ follow-up was updated on September 2018. The 
median test was used to compare quantitative variables, while 
the Chi-square or Fisher's exact tests were employed to assess 
differences in proportions. All comparisons were two-tailed. 
Curves for OS and event-free survival (EFS) were plotted ac-
cording to the Kaplan-Meier method and were compared by 
the log-rank test. The CIR was calculated using cumulative 
incidence functions by competing risks analysis, nonrelapse 
mortality (NRM) being the competing event. Data collection 
and statistical analyses were performed at the PETHEMA 
Data Center for ALL using SPSS v.24 and R v.3.5.2 software.
3 |  RESULTS
3.1 | Patients features at diagnosis
One-hundred and two patients were enrolled in 40 Spanish 
hospitals, 89 of whom were eligible for the study. The re-
maining 13 patients were excluded because age < 15 years 
(n  =  1), ALL with high-risk features at baseline (n  =  9), 
lymphoblastic lymphoma (n = 2), and Philadelphia chromo-
some-positive ALL (n = 1).
Table 2 shows the main clinical and biological fea-
tures of the whole series including adolescents (n  =  38) 
vs YA (n  =  51). Median age at diagnosis was 20  years 
(range 15-30  years) and 54 patients (61%) were males. 
Extramedullary disease was present at diagnosis in four 
cases (5%). Eighty-four patients (94%) had B-cell precur-
sor ALL. Twenty-three patients (26%) showed a normal 
karyotype. Abnormal karyotypes included high hyper-
diploidy (n = 8, 9%), t(1;19) (n = 4, 5%), t(12;21)(ETV6/
RUNX1) (n = 1, 1%) and del(9p) (n = 3, 3%), among oth-
ers. Four cases (5%) had a complex karyotype, an abnor-
mality not considered as HR at the time of protocol design. 
The absence or insufficient number of metaphases was reg-
istered in 28 (32%) cases. No significant differences were 
observed in karyotypic results on comparison between ad-
olescents and YA (Table 2).
3.2 | Treatment outcome
There were no deaths in induction. On day 14 of induction 
therapy 68 patients (76%) showed standard BM response 
while 21 patients (24%) showed slow response, and 20 of 
these latter patients were moved to a HR protocol; the re-
maining patient withdrew the study. All patients with stand-
ard early response achieved CR, and 16 of the remaining 20 
patients with slow response achieved CR with the induction 
therapy of the HR protocol (three patients were resistant 
and one was not evaluable due to withdrawal from the pro-
tocol during induction), for a total of 84 CR patients (95%) 
(Figure 1). Two CR patients with standard early cytologic 
response showed high MRD levels (0.8% and 0.75%, re-
spectively) at the end of induction and were then moved to 
a HR-ALL protocol. Thus, a total of 66 patients continued 
with the ALL RE08 trial, and 22 (10 adolescents and 12 YA) 
were transferred to a HR-ALL trial (7 to ALLHR03 and 15 to 
ALLHR11) (Figure 1).
At the time of the analysis 9/66 patients who followed 
the ALLRE08 trial were receiving consolidation or main-
tenance therapy at the time of the analysis, 8 patients re-
lapsed during consolidation (n = 3) or maintenance (n = 5) 
therapy and 11 patients relapsed off therapy. Seven patients 
abandoned the protocol due to excess toxicity (n = 4), their 
own decision (n  =  2) or a major deviation from the pro-
tocol (n  =  1). No therapy-related deaths were registered. 
Regarding those 18 patients in CR after inclusion in the 
HR protocol, 13 received chemotherapy and 5 allogeneic 
HSCT. Six patients relapsed (5 during chemotherapy and 
1 after HSCT), 1 died by toxicity of chemotherapy, and 
11 are in CR (7 after chemotherapy and 4 after HSCT). 
Fourteen patients remain alive (11 in first CR and 3 in sec-
ond CR).
Overall, 25 patients relapsed in either BM (n = 19) or 
BM plus CNS (n = 2), BM and testicle (n = 1) BM and 
lymph nodes (n = 1), CNS (n = 2) and testicular (n = 1). 
Ten patients were alive in second CR, one was alive in 
relapse, seven dead by treatment-related mortality (either 
by alloHSCT [n = 2] or by rescue chemotherapy [n = 5]) 
and seven dead by disease progression. The CIR at 5 years 
for the whole series was 35% (95%CI: 23%-47%) (Figure 
2A). With a median follow-up of 4.19 years (range 0.04-
9.47), 18 patients have died, with the OS probability at 
5 years being 74% (95%CI: 63%-85%) for the whole series 
(Figure 2B). The main causes of death were disease pro-
gression (n = 15), transplant-related (n = 2) and toxicity 
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of HR chemotherapy (n = 1). Fifty-one patients remained 
alive and off therapy (41 in first CR and 10 in second CR). 
Figure 2C shows the EFS for the whole series (probability 
at 5 years 62% [95%CI: 49%-73%]). Table 3 shows the main 
outcomes for both the whole series and for those patients 
who remained in the ALLRE08 protocol, those who were 
moved to a HR protocol, and for adolescents and YA con-
sidered separately. As shown, significant differences in OS 
and CIR were observed in adolescents vs YA, with 5 years. 
OS rates of 87% (95%CI: 74%-100%) vs 63% (46%-80%), 
respectively, P = 0.021 and CIR rates of 13% (4%-28%) vs 
52% (34%-67%), P = 0.012, respectively (Figures 3A,B). 
Interestingly, no significant differences were observed in 
the CIR in patients who remained in the ALLRE08 proto-
col vs those who were moved to a HR protocol (5-year CIR 
rate of 34% [21%-47%] vs 37% [14%-61%], respectively, 
P = 0.588) (Figure 4).
3.3 | MRD status
MRD at the end of the induction was evaluable in 61/68 pa-
tients with standard response. Of these, 53 showed MRD 
level < 0.1%, and 8 had MRD levels ≥ 0.1% (≥0.5% in two, 
who were moved to a HR protocol). Forty-eight patients 
showed end-induction MRD levels  <  0.05%. MRD levels 
postconsolidation were evaluable in 54/66 patients who began 
consolidation. The reasons for lack of MRD data in the re-
maining 12 patients were: early relapse (n = 3), withdrawal 
from protocol (n  =  1), protocol deviation (n  =  1), still on 
therapy (n  =  1), and no test performed (n  =  6). No patient 
was moved to a HR protocol at this time point, because the 
MRD level remained < 0.05% in all evaluable patients. From 
those 60 patients who began the maintenance therapy 47 had 
MRD assessed, while 13 did not because of relapse (n = 1), 
withdrawal from protocol (n = 5), still on therapy (n = 1) and 
Characteristic
Whole series 
(n = 89)
Adolescents 
(n = 38)
Young adults 
(n = 51) P value
Age at diagnosis, years, median 
(range)
20 (15-29) 17 (15-18) 23 (19-29) <0.001
Gender 0.197
Male 54 (61%) 26 (68%) 28 (55%)
Female 35 (39%) 12 (32%) 23 (45%)
Performance status (ECOG 
scale)
0.746
0 26 (30%) 13 (34%) 13/48 (27%)
1 52 (61%) 22 (58%) 30/48 (63%)
2 7 (8%) 3 (8%) 4/48 (8%)
3 1 (1%) 0 1/48 (2%)
Extramedullary disease NA
CNS 3 (3%) 0 3 (3%)
CNS + other 1 (1%) 0 1 (1%)
WBC count, x109/L, median 
(range)
6.83 (0.4-30) 6.82 
(0.4-24.8)
7.19 (0.8-30) 0.736
Phenotype 0.884
Early pre-B 0 0 0
Common 68 (76%) 30 (79%) 38 (74%)
Pre-B 16 (18%) 6 (16%) 10 (20%)
T 5 (6%) 2 (5%) 3 (6%)
Karyotype 0.452
No growth
Normal
28 (32%)
23 (26%)
9 (24%)
10 (26%)
19 (37%)
13 (25%)
Hyperdiploidy > 50 chr 8 (9%) 5 (13%) 3 (6%)
t(12;21)/TEL-AML1 1 (1%) 1 (3%) 0
t(1;19) 4 (5%) 2 (5%) 2 (4%)
Other abnormalities 25 11 (29%) 14 (28%)
Abbreviations: chr, chromosomes; CNS, central nervous system; ECOG, Eastern Cooperative Oncology 
Group; NA, not available; WBC, white blood cell.
T A B L E  2  Patient characteristics in the 
whole series and according to the age group
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MRD testing not performed (n = 6). Again, no patient was 
transferred to a HR protocol due to MRD levels  <  0.05%. 
MRD testing at end-of-therapy was performed in 27 patients. 
The remaining 24 patients had no MRD data because they had 
relapsed (n = 3), have just finished M-2 therapy (n = 6) or 
had missing data (n = 15). In 6/11 patients who relapsed off 
F I G U R E  1  Flow chart of the patients in the ALLRE08 PETHEMA trial
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therapy MRD levels at the end of maintenance were < 0.05% 
while were missing in the remaining five cases.
3.4 | Dose modifications and 
treatment toxicity
The dose of chemotherapy was delayed in 1/68 (1.5%) eval-
uable patients during induction, in 22/62 (35%) evaluable 
patients in C1, 10/55 (18%) evaluable patients in C2 and 
in 13/52 (25%) evaluable patients during maintenance. In 
addition, there were dose modifications of cytotoxic drugs 
in 2/68 (3%) evaluable patients during induction, in 8/62 
(13%) evaluable patients during C1, in 9/55 (16%) evalu-
able patients during C2, and in 34/52 (65%) patients during 
maintenance. No differences were found in the frequency of 
delays or dose modifications of the chemotherapy between 
adolescents and YA. Of note, OS and CIR were not signifi-
cantly different in patients who showed delays or dose mod-
ifications vs those who received the schedule timely and at 
full dose (5-year OS: 76% [62%-90%] vs 84% [64%-100%], 
P = 0.326; 5-year CIR: 32% [14%-46%] vs 27% [0%-47%], 
P = 0.920). Main grade III-IV toxicities observed in the trial 
(Table 4) were: i) hematologic, particularly in induction, C1 
and C2. Despite this relatively high frequency, the number 
of severe infections was low, ii) hepatic, and iii) hypersen-
sitivity to native E coli asparaginase. As expected, the lat-
ter was more frequent after its reexposure in C2 cycle or in 
M1. Erwinia asparaginase was given to 9 of 13 patients with 
grade III-IV allergic reactions, and removal of asparaginase 
was done in the remaining four cases.
3.5 | Patients outcome in the ALLRE08 
vs the ALL-96 PETHEMA trials
Table S1 shows the comparison of the main outcomes be-
tween these protocols. As expected, the outcomes were not 
significantly different, although a significantly lower OS was 
observed in YA vs adolescents in the current study and not in 
the ALL96 trial.
4 |  DISCUSSION
This study shows that treatment with a full pediatric protocol 
is feasible and effective for AYA with Ph-neg, SR-ALL, with 
better results for adolescents than for YA. Of note, one third 
of the patients showed poor early response, but their outcome 
was not significantly inferior than that observed for the good 
responders after being rescued with a HR therapy.
Adolescent and YA patients with ALL represent a popu-
lation with specific characteristics and needs.1-3 At present it 
is well established that adolescents aged 15 to 20 years are 
best treated with full pediatric protocols; in parallel, growing 
evidence suggests that this might also be true for YA (with 
an upper age limit of 30 to 40 years in most studies or even 
up to 50-55 years in some studies),15-18 with 5-year survival 
rates around 70%, despite HSCT is less used in pediatric 
trials. Since MRD has emerged as a powerful prognostic 
marker useful for risk stratification in ALL,19 the PETHEMA 
ALLRE08 trial added MRD assessment to the early cytologic 
response to select among AYA patients with SR-ALL those 
who were poor responders and transfer them to a HR proto-
col, while maintaining the full pediatric chemotherapy sched-
ule for good responders.
F I G U R E  2  Cumulative incidence of relapse (panel A), and 
overall survival (panel B) in the whole series
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Overall, the CR rate observed was high and similar to that 
reported for most full pediatric or pediatric-inspired proto-
cols focused on AYA with ALL.11,16-21 and those without 
a pediatric basis.21 Of note, one third of patients were poor 
responders and were transferred per protocol to a HR trial, 
which allowed CR to be attained in 80% of patients. No toxic 
toxicity-related deaths occurred among AYA who followed 
the ALLRE08 trial and the overall adherence to the protocol 
being good. Despite this a few patients abandoned the trial 
due to excess toxicity, their own decision or a major devia-
tion from the predefined therapeutic schedule. In contrast, a 
significant rate of relapses off therapy (11/19) occurred de-
spite the MRD levels were low in all tested cases. Because no 
regular MRD assessment was performed off therapy, early re-
emergence of MRD could not be identified and consequently 
early therapeutic intervention at an MRD positive CR status 
was not feasible in these patients. Whether or not prolonged 
maintenance therapy for 2.5 or 3 years from CR, as done in 
some pediatric protocols, would result in a lower frequency of 
late relapses among these patients remains to be investigated.
Among all treated patients those with poor early response 
were more difficult to treat, showing a higher rate of resistant 
leukemia and deaths by toxicity. It might well be that a more 
extensive work-up of ALL at diagnosis would allow identifi-
cation of patients with poor genetic risk (eg, BCR-ABL1-like 
ALL) among this group of patients.22 However, still 80% of 
cases with slow response treated with a HR trial achieved 
CR. For these patients allogeneic HSCT was performed ac-
cording to physicians’ criteria, resulting in only 5/18 CR pa-
tients (including the two patients who had an excess of MRD 
at the end of the first induction) being transplanted, a propor-
tion that is clearly lower than that expected for ALL patients 
presenting chemoresistance. As expected for HR ALL, one 
third of the patients relapsed.7 It could be speculated that 
the proportion of relapses would have been lower if all pa-
tients had undergone allogeneic HSCT, as the frequency of 
relapses was lower in transplanted than in nontransplanted 
patients (1/5 for allogeneic HSCT vs 5/13 for chemotherapy), 
but the low number of cases in this series does not allow to 
draw definitive conclusions. Despite the OS for these patients 
was lower (and the CIR slightly higher) than that observed 
for patients showing good early response, the differences did 
not reach statistical significance, indicating that a substantial 
proportion of these patients can be successfully rescued if 
they are transferred early to a HR protocols. However, the 
absence of statistically significant differences in OS between 
patients on trial on those who were rescued in HR trials does 
not mean that the rescue therapy was really very effective 
(40% of relapses). It is clear that other approaches are nec-
essary to improve the prognosis of this subset of patients, as 
discussed later in this section.
Although the OS rates observed in the ALLRE08 and 
the ALL96 trials were equivalent, some differences should 
be pointed out. Thus, while no differences existed in the 
inclusion criteria and the baseline characteristics of the pa-
tients enrolled in both trials, significantly lower OS rates 
were observed in the here reported trial for YA vs adoles-
cents, not being observed in the ALL96 trial, where the 
two groups of patients showed similar outcome.12 This 
might be due to a better OS of adolescents in the ALLRE08 
trial vs the ALL96 study (87% [74%-100%] vs 80% [67%-
93%]) and a lower OS for YA (as a consequence of a higher 
CIR) in this vs the previous trial (63% [46%-80%] vs 71% 
[58%-84%]) emphasizing in the ALLRE08 trial the overall 
Patient group N
OS (5-yrs, 
95% CI)
EFS (5-yrs, 
95% CI)
CIR (5-yrs, 
95% CI)
Whole series 89 74%
(63%;85%)
62%
(49%;73%)
35%
(23%;47%)
Patients that remained in the 
ALLRE08 trial
66 78%a
(66%;90%)
67%e
(51%;78%)
34%ab
(21%;47%)
Patients moved to HR trials 22 61%a
(31%;91%)
48%e
(25%;68%)
37%b
(14%;61%)
Adolescents 38 87%c
(74%;100%)
78%f
(59%,;89%)
13%d
(4%;28%)
Young adults 51 63%c
(46%;80%)
49%f
(31%;65%)
52%d
(34%;67%)
Abbreviations: CIR, cumulative incidence of relapse; EFS, event-free survival; HR, high risk; OS, overall 
survival.
ap = 0.343 
bp = 0.588 
cp = 0.021 
dp = 0.012 
ep = 0.028 
fp = 0.151 
T A B L E  3  Main outcomes of the 
patients from the whole series, for those 
who remained in the ALLRE08 protocol 
and those who were moved to high-risk 
protocol, and for adolescents and young 
adults separately
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difference in OS observed between adolescents and YA, 
that was already present at a nonsignificant level in the 
ALL96 trial.13
Overall, the tolerability of the ALLRE08 trial was 
good, probably due to the relatively conservative upper 
age limit for inclusion, set at 30  years. Main toxic 
events were due to cytopenias and infections, followed 
by liver toxicity and hypersensitivity to E coli aspar-
aginase. Although the frequency of delays and dose 
modification of the chemotherapeutic drugs were high, 
especially during maintenance, there were no differ-
ences between adolescents and YA, and these modifi-
cations did not show impact on patients’ outcome. Dose 
modifications and delays are important in the pediatric 
setting, but their relevance in AYA and adults has been 
less studied.
Despite the long follow-up of the patients here reported, 
some limitations should be pointed out for this trial. First, 
the definition of risk factors did not take into account im-
portant features such as deep molecular characterization of 
the patients at baseline aimed to detect specific gene dele-
tions/mutations, as well as other important characteristics 
with recognized prognostic impact such as the BCR-ABL 
like signature or the early pre-T signature, that are frequent 
among AYA,22-24 although the latter subgroups were identi-
fied when the trial was in an advanced phase of recruitment. 
It is clear that at present the risk definition should include 
the aforementioned studies. Second, combined cytological 
and MRD criteria were used to identify poor early respond-
ers, but only two patients were transferred to a HR protocol 
because of poor MRD clearance. Despite the early cytolog-
ical response has been extensively used in the past for early 
identification of this subset of patients resistant to induction 
therapy, and has prognostic significance,25 most modern 
trials use end-induction MRD as the only tool to assess the 
quality of response, given that there is not a precise correla-
tion between poor early cytological response and the pattern 
of MRD clearance.11 In turn, the end-induction MRD cut-off 
(0.25%) selected for transferring the patients to a HR trial 
F I G U R E  3  Comparison between the overall survival (panel A), 
and the cumulative incidence of relapse (panel B) between adolescents 
and young adults
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can be considered too high, since most modern trials con-
sider lower MRD cut-offs (>0.1% or even > 0.01%) to define 
poor MRD response after induction. Third, MRD was not 
centrally assessed, and consequently introduced a potential 
bias in the study, potential impact on the reproducibility of 
the results. In addition, the MRD was assessed by 4-color 
FCM, a technique known now to provide insufficient sensi-
tivity. Finally, the study was restricted to AYA with SR fea-
tures, which might limit direct comparison with other trials 
that include AYA with Ph-negative ALL, only selected by 
age.
At present, there is room for improvement of patients 
outcome after pediatric type therapy in AYA with Ph-neg 
ALL, and according to our results, this improvement is 
especially necessary for YA.26 The more extensive use 
of conventional drugs such as PEG-asparaginase11,17 to-
gether with the early incorporation of immunotherapeutic 
approaches with naked (anti CD20),27 immunoconjugated 
(inotuzumab ozogamicin),28 or bispecific (blinatum-
omab)29,30 monoclonal antibodies which have proven ef-
fective in relapsed/refractory or MRD positive patients 
might contribute to improve the quality of remission and 
decreased the relapse rate observed in our study. In addi-
tion, early use of genetically engineered T cells that rec-
ognize ALL epitopes (CAR T cells) will also provide an 
opportunity to improve the outcomes of these patients.31-33 
Finally, incorporation of targeted kinase inhibitors to 
pediatric type chemotherapeutic regimens for specific 
subtypes of ALL such as BCR-ABL like might further con-
tribute to overcome the resistance to therapy and improve 
survival of this particularly difficult to treat subgroup of 
ALL patients.
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T A B L E  4  Main grade III-IV toxicities observed per treatment phases of the ALLRE08 trial
Induction Consolidation Reinduction
Maintenance with 
reinforcements
Neutropenia
Days, median [min;max]
55/67 (82%)
15 [1; 41]
34/58 (59%)
6 [1; 30]
26/56 (46%)
3,50 [1 ;13]
5/52 (10%)
Thrombocytopenia
Days, median [min;max]
26/65 (40%)
8 [1; 35]
8/58 (14%)
3 [1; 13]
1/55 (2%)
3
0
Coagulation disorders 9/67 (13%) 1/59 (2%) 1/56 (2%) 0
Infection 21/65 (32%) 14/59 (24%) 5/56 (9%) 1/52 (2%)
Hypersensitivity 0 1/59 (2%) 8/56 (14%) 4/52 (8%)
Neurologic 2/68 (3%) 0 2/56 (4%) 1/52 (2%)
Hepatic 13/68 (19%) 8/58 (14%) 5/56 (9%) 6/52(12%)
Renal 0 2/59 (3%) 0 0
Gastrointestinal 0 0 1/56 (2%) 0
Vascular 2/67 (3%) 0 1/56 (2%) 0
Pulmonary 0 0 1/56 (2%) 1/52 (2%)
Metabolic 2/67 (3%) 0 0 0
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